Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Inoue, Daichi  [Clear All Filters]
2023
Tanaka A, Nishimura K, Saika W, Kon A, Koike Y, Tatsumi H, Takeda J, Nomura M, Zang W, Nakayama M, et al. SETBP1 is dispensable for normal and malignant hematopoiesis. Leukemia. 2023.
Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, et al. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. Nat Cancer. 2023.
2022
Hayashi Y, Kawabata KC, Tanaka Y, Uehara Y, Mabuchi Y, Murakami K, Nishiyama A, Kiryu S, Yoshioka Y, Ota Y, et al. MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis. Cell Rep. 2022;39(6):110805.
2020
Takeda R, Asada S, Park S-J, Yokoyama A, Becker HJiro, Kanai A, Visconte V, Hershberger CE, Hayashi Y, Yonezawa T, et al. HHEX promotes myeloid transformation in cooperation with mutant ASXL1. Blood. 2020.
2018
Lee SChun-Wei, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, et al. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018;34(2):225-241.e8.
2015
Kitamura T, Watanabe-Okochi N, Enomoto Y, Nakahara F, Oki T, Komeno Y, Kato N, Doki N, Uchida T, Kagiyama Y, et al. Novel working hypothesis for pathogenesis of hematological malignancies: Combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). J Biochem. 2015.